← Leaderboards
Sherie L Morrison
University Of California Los Angeles
$12,725,119
Attributed
$12,725,119
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$12,725,119 · 10
By mechanism
R01$8,327,259 · 6
U01$1,759,494 · 1
R37$1,642,610 · 1
P30$572,256 · 1
R21$423,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Tracy Ruth Daniels-Wells$1,066,259
- Miklos Sahin-Toth$15,868,141
- David O Beenhouwer$3,874,314
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseChimeric ProteinsImmunoglobulin AImmunoglobulin GProteinsIn VitroAntibodiesIn VivoImmune ResponseCell LineSiteNeutralizing AntibodyComplementAntigensToxic EffectCellsEnzyme Linked Immunosorbent AssayRecombinant ProteinsTumorNonhuman Therapy EvaluationMalignant NeoplasmsSite Directed MutagenesisExhibitsPathway Interactions
Grant awards (45)
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma$352,275
R01 · FY2020 · CA · contact PI
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma$341,706
R01 · FY2019 · CA · contact PI
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma$352,275
R01 · FY2018 · CA · contact PI
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma$352,275
R01 · FY2017 · CA · contact PI
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma$352,275
R01 · FY2016 · CA · contact PI
Antibody-interferon fusion proteins for treatment of B-cell malignancies$319,550
R01 · FY2015 · CA · contact PI
Antibody-interferon fusion proteins for treatment of B-cell malignancies$309,964
R01 · FY2014 · CA · contact PI
Antibody-interferon fusion proteins for treatment of B-cell malignancies$300,377
R01 · FY2013 · CA · contact PI
Antibody-interferon fusion proteins for treatment of B-cell malignancies$319,550
R01 · FY2012 · CA · contact PI
Effector Functions of Mucosal IgA$192,500
R21 · FY2012 · AI · contact PI
Antibody-interferon fusion proteins for treatment of B-cell malignancies$319,550
R01 · FY2011 · CA · contact PI
Effector Functions of Mucosal IgA$231,000
R21 · FY2011 · AI · contact PI
Non-Immunogenic ADEPT: Human Enzymes & Delivery Vehicles$234,391
R01 · FY2008 · GM · contact PI
Immunotherapeutics to Prevent & Treat Botulinum Toxin Intoxication$384,943
U01 · FY2007 · AI · contact PI
MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS$289,195
R01 · FY2007 · AI · contact PI
Non-Immunogenic ADEPT: Human Enzymes & Delivery Vehicles$234,391
R01 · FY2007 · GM · contact PI
Immunotherapeutics to Prevent & Treat BoNT Intoxication$386,354
U01 · FY2006 · AI · contact PI
MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS$297,833
R01 · FY2006 · AI · contact PI
Non-Immunogenic ADEPT: Human Enzymes & Delivery Vehicles$241,391
R01 · FY2006 · GM · contact PI
Immunotherapeutics to Prevent &Treat BoNT Intoxication$384,392
U01 · FY2005 · AI
MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS$305,000
R01 · FY2005 · AI
GLYCOSYLATION AND ANTIBODY FUNCTION$301,034
R37 · FY2005 · AI
Non-Immunogenic ADEPT: Human Enzymes &Delivery Vehicles$268,926
R01 · FY2005 · GM
Immunotherapeutics to Prevent &Treat BoNT Intoxication$385,286
U01 · FY2004 · AI
MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS$305,000
R01 · FY2004 · AI
GLYCOSYLATION AND ANTIBODY FUNCTION$292,442
R37 · FY2004 · AI
RECOMBINANT ANTIBODIES FOR INFANT PROTECTION$265,096
R01 · FY2004 · AI
AB FUSION PROTEINS AS SYSTEMIC BRAIN DELIVERY VEHICLES$205,875
R01 · FY2004 · CA
MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS$326,640
R01 · FY2003 · AI
GLYCOSYLATION AND ANTIBODY FUNCTION$284,099
R37 · FY2003 · AI
RECOMBINANT ANTIBODIES FOR INFANT PROTECTION$265,096
R01 · FY2003 · AI
Immunotherapeutics to Prevent &Treat BoNT Intoxication$218,519
U01 · FY2003 · AI
AB FUSION PROTEINS AS SYSTEMIC BRAIN DELIVERY VEHICLES$205,875
R01 · FY2003 · CA
RECOMBINANT ANTIBODIES FOR INFANT PROTECTION$364,718
R01 · FY2002 · AI
GLYCOSYLATION AND ANTIBODY FUNCTION$276,218
R37 · FY2002 · AI
AB FUSION PROTEINS AS SYSTEMIC BRAIN DELIVERY VEHICLES$205,988
R01 · FY2002 · CA
CORE--MEDIA PREPARATION$167,178
P30 · FY2002 · CA
GLYCOSYLATION AND ANTIBODY FUNCTION$268,984
R37 · FY2001 · AI
RECOMBINANT ANTIBODIES FOR INFANT PROTECTION$265,811
R01 · FY2001 · AI
AB FUSION PROTEINS AS SYSTEMIC BRAIN DELIVERY VEHICLES$206,550
R01 · FY2001 · CA
CORE--MEDIA PREPARATION$167,178
P30 · FY2001 · CA
RECOMBINANT ANTIBODIES FOR INFANT PROTECTION$290,636
R01 · FY2000 · AI
CORE--MEDIA PREPARATION$237,900
P30 · FY2000 · CA
AB FUSION PROTEINS AS SYSTEMIC BRAIN DELIVERY VEHICLES$229,050
R01 · FY2000 · CA
GLYCOSYLATION AND ANTIBODY FUNCTION$219,833
R37 · FY2000 · AI